These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 5975562)
21. Implementing accountability for reasonableness--the case of pharmaceutical reimbursement in Sweden. Jansson S Health Econ Policy Law; 2007 Apr; 2(Pt 2):153-71. PubMed ID: 18634660 [TBL] [Abstract][Full Text] [Related]
22. The drug-device interface. Cutler IR Med Device Technol; 1993 Jun; 4(5):48-51. PubMed ID: 10171678 [TBL] [Abstract][Full Text] [Related]
24. Significance of Drugs and Cosmetics Rules in general practice. Sarker BB Indian Med J; 1967 Jan; 61(1):22-3. PubMed ID: 6037500 [No Abstract] [Full Text] [Related]
25. Defending an emerging threat: consumer fraud class action suits in pharmaceutical and medical device products-based litigation. Leghorn JJ; Allen C; Brewington T Food Drug Law J; 2006; 61(3):519-38. PubMed ID: 16989037 [No Abstract] [Full Text] [Related]
26. One decade of food and drug law scholarship: a selected bibliography. Noah L Food Drug Law J; 2000; 55(4):641-58. PubMed ID: 12025854 [No Abstract] [Full Text] [Related]
27. Reimbursement for drugs -- a register study comparing economic outcome for five healthcare centres in areas with different socioeconomic conditions. Semark B; Fredlund K; Astrand B; Brudin L Scand J Public Health; 2009 Aug; 37(6):647-53. PubMed ID: 19546143 [TBL] [Abstract][Full Text] [Related]
28. [Organization of control of pharmaceutical specialties in Sweden]. CANBACK T Minerva Farm; 1952 Dec; 1(1):40-1. PubMed ID: 13046201 [No Abstract] [Full Text] [Related]
29. Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective. Bergström G; Karlberg I Health Policy; 2007 May; 81(2-3):358-67. PubMed ID: 16942815 [TBL] [Abstract][Full Text] [Related]
30. DISPENSING of drugs by physicians and their employees. Wis Med J; 1955 Jan; 54(1):48-50. PubMed ID: 14348938 [No Abstract] [Full Text] [Related]
31. Repeat prescriptions: refill adherence in relation to patient and prescriber characteristics, reimbursement level and type of medication. Andersson K; Melander A; Svensson C; Lind O; Nilsson JL Eur J Public Health; 2005 Dec; 15(6):621-6. PubMed ID: 16126746 [TBL] [Abstract][Full Text] [Related]
32. [Czechoslovak mass produced medicinal preparations, their number and composition]. Dofková L Cesk Farm; 1967 May; 16(4):208-11. PubMed ID: 6080494 [No Abstract] [Full Text] [Related]
33. Report from Ottawa. Waring G Can Med Assoc J; 1968 Sep; 99(9):424. PubMed ID: 5703281 [No Abstract] [Full Text] [Related]
34. [Drug addicts in the present commitment legislation]. SENIGAGLIA V Rass Studi Psichiatr; 1950; 39(5-6):791-5. PubMed ID: 14808642 [No Abstract] [Full Text] [Related]
35. Banned -- Select: "a drug to alter the sex of the foetus". Unnikrishnan PV Health Millions; 1993 Apr; 1(2):29-30. PubMed ID: 12286470 [TBL] [Abstract][Full Text] [Related]
36. Does the FDA have authority to regulate human cloning? Price EC Harv J Law Technol; 1998; 11(3):619-41. PubMed ID: 12731551 [No Abstract] [Full Text] [Related]
37. [Who should guarantee research ethics? Voluntary scrutiny is better than the one prescribed by law]. Jacobsson L Lakartidningen; 1997 Jul; 94(30-31):2623-4. PubMed ID: 9273411 [No Abstract] [Full Text] [Related]
38. TRIPS [letter]. Church D Br J Gen Pract; 2001 Dec; 51(473):1014. PubMed ID: 11766856 [No Abstract] [Full Text] [Related]
39. The impact of the new products liability Restatement on prescription products. Schwartz TM Food Drug Law J; 1995; 50(3):399-413. PubMed ID: 10343009 [No Abstract] [Full Text] [Related]
40. Fixed budgets as a cost containment measure for pharmaceuticals. Granlund D; Rudholm N; Wikström M Eur J Health Econ; 2006 Mar; 7(1):37-45. PubMed ID: 16435117 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]